{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:01:55Z","timestamp":1777676515171,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T00:00:00Z","timestamp":1544227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010248","name":"Zhejiang Province Public Welfare Technology Application Research Project","doi-asserted-by":"publisher","award":["2013C33094"],"award-info":[{"award-number":["2013C33094"]}],"id":[{"id":"10.13039\/501100010248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.biopha.2018.12.039","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:08:47Z","timestamp":1544789327000},"page":"844-849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-2528","authenticated-orcid":false,"given":"Keyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shourong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiantu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kechen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangbin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2018.12.039_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MEG.0000000000000507","article-title":"Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"28","author":"Gong","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.039_bib0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1590-8658(02)80194-3","article-title":"Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study","volume":"34","author":"Lonardo","year":"2002","journal-title":"Digest. Liver Dis."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.039_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/MEG.0000000000000931","article-title":"Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Jaruvongvanich","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"7384","key":"10.1016\/j.biopha.2018.12.039_bib0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.039_bib0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2016.12.025","article-title":"Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents","volume":"66","author":"Mosca","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.039_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22020277","article-title":"Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer\u2019s disease","volume":"22","author":"Loureiro","year":"2017","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"7-8","key":"10.1016\/j.biopha.2018.12.039_bib0035","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.nut.2013.11.016","article-title":"Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation","volume":"30","author":"Andrade","year":"2014","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.039_bib0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial","volume":"47","author":"Chen","year":"2015","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.039_bib0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1590\/1414-431x20144032","article-title":"Resveratrol inhibits the intracellular calcium increase and angiotensin\/endothelin system activation induced by soluble uric acid in mesangial cells","volume":"48","author":"Albertoni","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.039_bib0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.23167","article-title":"Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis","volume":"50","author":"Witek","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.039_bib0055","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hep.23717","article-title":"Association between serum uric acid level and chronic liver disease in the United States","volume":"52","author":"Afzali","year":"2010","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.039_bib0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.gastro.2010.11.002","article-title":"Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C","volume":"140","author":"Conjeevaram","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.039_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004840","article-title":"Hepatitis D virus infection of mice expressing human sodium taurocholate co-transporting polypeptide","volume":"11","author":"He","year":"2015","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.039_bib0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.039_bib0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.phrs.2012.05.003","article-title":"Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats","volume":"66","author":"Bagul","year":"2012","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.039_bib0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12020-016-0896-7","article-title":"SIRT1 prevents hyperuricemia via the PGC-1alpha\/PPARgamma-ABCG2 pathway","volume":"53","author":"Wang","year":"2016","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.biopha.2018.12.039_bib0085","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/mnfr.201100828","article-title":"Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice","volume":"56","author":"Shi","year":"2012","journal-title":"Mol. Nutr. Food Res."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.039_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201601030","article-title":"Negative correlation between serum uric acid and kidney URAT1 mRNA expression caused by resveratrol in rats","volume":"61","author":"Lee","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"issue":"11","key":"10.1016\/j.biopha.2018.12.039_bib0095","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/liv.12842","article-title":"The association between serum levels of uric-acid and alanine aminotransferase in a population-based cohort","volume":"35","author":"Zelbersagi","year":"2015","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.039_bib0100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0168-8278(03)80033-8","article-title":"Insulin resistance (IR) but not reduced insulin secretion (IS) is associated to non alcoholic fatty liver disease (NAFLD)","volume":"38","author":"Angelico","year":"2003","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.039_bib0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","article-title":"Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism","volume":"64","author":"Wan","year":"2016","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.039_bib0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-39781","article-title":"Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes","volume":"111","author":"Boden","year":"2003","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.039_bib0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.numecd.2008.12.015","article-title":"Hepatic lipid metabolism and non-alcoholic fatty liver disease","volume":"19","author":"Tessari","year":"2009","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.039_bib0120","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.bbadis.2018.05.003","article-title":"The role of xanthine oxidoreductase and uric acid in metabolic syndrome","volume":"1864","author":"Battelli","year":"2018","journal-title":"Biochim. Biophys, Acta Mol. Basis Dis."},{"issue":"6904","key":"10.1016\/j.biopha.2018.12.039_bib0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature01036","article-title":"Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress","volume":"419","author":"Kops","year":"2002","journal-title":"Nature"},{"issue":"5666","key":"10.1016\/j.biopha.2018.12.039_bib0130","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.1094637","article-title":"Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase","volume":"303","author":"Brunet","year":"2004","journal-title":"Science (New York, N.Y.)"},{"issue":"13","key":"10.1016\/j.biopha.2018.12.039_bib0135","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1089\/ars.2012.4713","article-title":"SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a\/PGC-1\u03b1 complex","volume":"19","author":"Olmos","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.biopha.2018.12.039_bib0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.redox.2017.09.016","article-title":"Sirt1-Sirt3 axis regulates human blood-brain barrier permeability in response to ischemia","volume":"14","author":"Chen","year":"2018","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.039_bib0145","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.27341","article-title":"Cholangiocyte lipoapoptosis: implications for biliary damage during nonalcoholic fatty liver disease","volume":"60","author":"Martinez","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"6","key":"10.1016\/j.biopha.2018.12.039_bib0150","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.27175","article-title":"Saturated free fatty acids induce cholangiocyte lipoapoptosis","volume":"60","author":"Natarajan","year":"2014","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.039_bib0155","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbrc.2015.02.029","article-title":"NLRP3 inflammasome expression is driven by NF-kappaB in cultured hepatocytes","volume":"458","author":"Boaru","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"21","key":"10.1016\/j.biopha.2018.12.039_bib0160","doi-asserted-by":"crossref","first-page":"34258","DOI":"10.18632\/oncotarget.15946","article-title":"Foxo3a-dependent Bim transcription protects mice from a high fat diet via inhibition of activation of the NLRP3 inflammasome by facilitating autophagy flux in Kupffer cells","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"1-2","key":"10.1016\/j.biopha.2018.12.039_bib0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11010-016-2807-x","article-title":"Resveratrol supplement inhibited the NF-kappaB inflammation pathway through activating AMPKalpha-SIRT1 pathway in mice with fatty liver","volume":"422","author":"Tian","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2018.12.039_bib0170","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.phrs.2016.08.010","article-title":"Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial","volume":"111","author":"Bo","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.039_bib0175","doi-asserted-by":"crossref","DOI":"10.3390\/nu10091153","article-title":"Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence","volume":"10","author":"Cicero","year":"2018","journal-title":"Nutrients"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218378983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218378983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:18:46Z","timestamp":1764105526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218378983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"alternative-id":["S0753332218378983"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.039","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}